1. Introduction {#s0005}
===============

Opioid signaling is triggered by endogenous opioid peptides comprising endorphins, enkephalins and dynorphins with preferential selectivities at the μ-, κ- and δ-opioid receptors, respectively [@bb0005]. The existence of opioid binding sites in the brain was established in 1973 [@bb0010] and subsequently located in various different physiological systems. In peripheral [@bb0015], [@bb0020] and central [@bb0025], [@bb0030], [@bb0035] parts of the nociceptive system, activation confers an effective nocifensive mechanism. Activation at the *Area postrema* causes respiratory depression [@bb0040], activation in brain areas belonging to the reward system [@bb0045] is involved in addiction [@bb0050], [@bb0055], [@bb0060], activation in the gastrointestinal tract causes constipation [@bb0065], and activation at the hypothalamic--pituitary--adrenal (HPA) axis is involved in stress responses [@bb0070].

Genetic variation of human opioid receptors is an active research topic that has identified several possible modulators of the individual response to endogenous and exogenous opioids [@bb0075]. Variants were associated with the modulation of opioid receptor expression [@bb0080], [@bb0085] or signaling [@bb0085], [@bb0090], [@bb0095] up to an almost complete functional loss [@bb0090], [@bb0100]. However, the collection of certain opioid receptor variants has provided only modest explanations of clinical phenotypes [@bb0105], [@bb0110]. Therefore, a limited selection of functional opioid receptor variants for which specific genetic assays had been established [@bb0115] is perceived as insufficient in providing a genetic diagnosis of the clinical phenotype [@bb0120].

Since the early 70th of the last century when the first processes of Sanger sequencing were introduced [@bb0125], [@bb0130], the access to the whole genomic information has been widely accepted as a valuable method in clinical research [@bb0135]. With the recent broader availability of next generation sequencing (NGS) [@bb0140] the limitation to known functional variants has therefore fallen in favor of unrestricted access to opioid receptor genetics, which has already been shown to provide a working genetic marker for opioid-related clinical phenotypes [@bb0145]. In this report, the evaluation of a new NGS method based on a custom AmpliSeq™ library and Ion Torrent sequencing for the fast detection of genetic variations in human opioid receptor genes is described.

2. Methods {#s0010}
==========

2.1. Gene selection {#s0015}
-------------------

Exomic genotyping was performed for the human *OPRM1*, *OPRK1* and *OPRD1* genes (NCBI IDs 4985, 4988 and 4986), located on chromosomes 6, 8, and 1, and encoding for the three major (μ, κ, δ) opioid receptors. Their endogenous ligands are opioid neuropeptides comprising endorphins/endomorphines, dynorphins, enkephalins, respectively, and they are the main targets of opioid analgesics as listed in the DrugBank database (version 4.1; <http://www.drugbank.ca> [@bb0150]). In particular *OPRM1* is addressed by most exogenous opioids. In addition, the *SIGMAR1* gene (NCBI ID [10280](ncbi-mmdb:10280){#ir0010}) located on chromosome 9, was included that codes for σ~1~-opioid receptors. These are not activated or blocked by opioid peptides or naloxone, respectively, however, historically belong to the opioid receptors [@bb0155], are targets of some drugs classified as opioids such as pentazocine [@bb0160] or dextromethorphan [@bb0165] and their activation modulates peripheral μ-opioid analgesia [@bb0170]. Furthermore, the gene panel was extended to the opiate receptor-like 1 gene (*OPRL1*; NCBI ID 4987), located on chromosome 20 and coding for the nociceptin receptor that shows a high degree of structural homology to the classical opioid receptors although opioid peptides or morphine-like compounds have little or no affinity for it [@bb0175]. Its endogenous ligand is nociceptin, however, exogenous opioids comprising buprenorphine [@bb0180] and its glucuronide metabolites [@bb0185] have been shown to exert agonist activity that seems to contribute to their clinical effects, and the nonselective opioid agonist etorphine also binds at the *OPRL1* gene product [@bb0190], which supports the inclusion of this gene in the present panel.

2.2. DNA template preparation and amplification {#s0020}
-----------------------------------------------

The investigation followed the Declaration of Helsinki on Biomedical Research Involving Human Subjects and was approved by the Ethics Committee of the Medical Faculty of the Goethe-University, Frankfurt, Germany. All subjects had provided informed written consent covering the genotyping. Genomic DNA was available from venous blood samples drawn from 79 pain patients in a previously reported [@bb0145] context of the pharmacogenomics of opioid dosing requirements.

DNA was extracted from 200 μl blood on a BioRobot EZ1 workstation applying the blood and body fluid spin protocol provided in the EZ1 DNA Blood 200 μl Kit (Qiagen, Hilden, Germany). A multiplex PCR amplification strategy for the coding DNA sequences was accomplished online (Ion Ampliseq™ Designer; <http://www.ampliseq.com>) to amplify the target region specified above (for primer sequences, see Supplementary Table 1) with 25 base pair exon padding. After a comparison of several primer design options, the design providing the maximum target sequence coverage was chosen. The ordered amplicons covered approximately 90% of the target sequence ([Table 1](#t0005){ref-type="table"}). A total of 10 ng DNA per sample were used for the target enrichment by a multiplex PCR and each DNA pool was amplified with the Ion Ampliseq™ Library Kit in conjunction with the Ion Ampliseq™ "custom Primer Pool" - protocols according to the manufacturer procedures (Life Technologies, Darmstadt, Germany).

After each pool had undergone 17 PCR cycles, the PCR primers were removed with FuPa Reagent and the amplicons were ligated to the sequencing adaptors with short stretches of index sequences (barcodes) that enabled sample multiplexing for subsequent steps (Ion Xpress™ Barcode Adapters Kit; Life Technologies). After purification with AMPure XP beads (Beckman Coulter, Krefeld, Germany), the barcoded libraries were quantified with a Qubit® 2.0 Fluorimeter (Life Technologies, Darmstadt, Germany) and normalized for DNA concentration to a final concentration of 20 pmol/l using the Ion Library Equalizer™ Kit (Life Technologies, Darmstadt, Germany). Equalized barcoded libraries from 11 to 12 samples at a time were pooled. To clonally amplify the library DNA onto the Ion Sphere Particles (ISPs; Life Technologies, Darmstadt, Germany), the library pool was subjected to emulsion PCR by using an IT OneTouch template kit on an IT OneTouch system (Life Technologies, Darmstadt, Germany) following the manufacturer\'s protocol.

2.3. Sequencing {#s0025}
---------------

Enriched ISPs which carried many copies of the same DNA fragment were subjected to sequencing on an Ion 316 Chip to sequence pooled libraries with eleven to twelve samples. The 316 chip was chosen (instead of the low-capacity 314 or the high-capacity 318 chip) to obtain a mean sequencing depth of coverage of 50 × which means that, on average, each base has been sequenced 50 ×, when eleven samples were loaded. A larger number of samples could be analyzed simultaneously using the 318 chip, but this would increase the turnaround time for each sample, depending on the number of samples that are received by the laboratory. Sequencing was performed using the sequencing kit (Ion PGM 200 Sequencing Kit; Life Technologies, Darmstadt, Germany) as per the manufacturer\'s instructions with the 200-bp single-end run configuration.

2.4. Bioinformatics generation of sequence information {#s0030}
------------------------------------------------------

The raw data (unmapped BAM-files) from the sequencing runs were processed using Torrent Suite Software (Version 4.4.2, Life Technologies, Darmstadt, Germany) to generate read alignments which are filtered by the software into mapped BAM-files using the reference genomic sequence (hg19) of target genes. Variant calling was performed with the Torrent Variant Caller Plugin using as key parameters: minimum allele frequency = 0.015, minimum quality = 10, minimum coverage = 20 and minimum coverage on either strand = 3.

The annotation of called variants was done using the Ion Reporter Software (Version 4.4; Life Technologies, Darmstadt, Germany) for the VCF files that contained the nucleotide reads. The GenomeBrowse® software (Version 2.0.4, Golden Helix, Bozeman, MT, USA) was used to map the observed sequences to the reference sequences GRCh37 hg19 (dated February 2009). The SNP and Variation Suite software (Version 8.4.4; Golden Helix, Bozeman, MT, USA) was used for the analysis of sequence quality, coverage and also for variant identification.

2.5. Method validation {#s0035}
----------------------

For method validation, two genomic regions were chosen at random from the whole analyzed region for validation by Sanger sequencing [@bb0125], [@bb0130] in an independent external laboratory (AGOWA, Berlin, Germany), which was performed in ten DNA samples randomly chosen from the n = 79 samples in the present cohort. Amplification of the respective DNA segments was done using PCR primer pairs (forward, reverse) of (i) 5´-ATGAAGACAGCAACCAACATTTAC-3´ and 5´-CCAGATGCAGATATTGATGATCTT-3´ and (ii) 5´-TTTAACCTGGCTTTGGCAGATG-3´ and 5´-ACATCGACGTCTTCCCTGACT-3´. The results of Sanger sequencing were aligned with the genomic sequence and analyzed using Chromas Lite® (Version 2.1.1, Technelysium Pty Ltd., South Brisbane, Australia) and the GenomeBrowse® (Version 2.0.4, Golden Helix, Bozeman, MT, USA) was used to compare the sequences obtained with NGS or Sanger techniques.

3. Results {#s0040}
==========

The NGS assay of human opioid receptors was established on 79 genomic DNA samples [@bb0145]. As proposed previously [@bb0195], only exons and their boundary sequences for which read-depths \> 20 for each nucleotide could be obtained were considered as successfully analyzed. Applying this criterion, complete or nearly complete coverage of the relevant sequences was obtained ([Table 1](#t0005){ref-type="table"}; for details on missing variants, see Supplementary Table 2).

The sequencing of the whole cohort required seven separate runs with each 11--12 patients\' samples. Coverage statistics ([Table 1](#t0005){ref-type="table"}) were comparable among all runs and were in the range of accepted quality criteria [@bb0200], [@bb0205], [@bb0210]. During the seven runs, a median of 2.54 × 10^6^ reads per run was generated. The mean depth was near from 200 reads, the mean read length evaluated 163 bases and average chip loading ([Fig. 1](#f0005){ref-type="fig"}) was 62%. To ensure a high density of ISPs on a chip and hence, a high sequencing output, the chip loading value should be ≥ 60% ([Table 2](#t0010){ref-type="table"}). The observed NGS results matched with the results obtained with conventional sequencing of random samples ([Fig. 2](#f0010){ref-type="fig"}). In all validation samples, the correspondence between NGS and Sanger derived nucleotide sequences was 100%.

From the NGS runs, a total of 35,447 nucleotides were read from each DNA sample. Following elimination of nucleotides agreeing with the standard human genome sequence GRCh37 hg19 (dated February 2009), the final result of the NGS consisted of a vector of nucleotide information for each individual DNA sample. This vector had a length equaling the number of chromosomal positions in which a non-reference nucleotide had been found in any probe of the actual study sample. In the 28 pain patients who required standard opioid doses for analgesia (for clinical details, see [@bb0145]) and could therefore substitute for a random sample with respect to opioid receptor genetics, these vectors had a length of 91 nucleotides ([Fig. 3](#f0015){ref-type="fig"}). They included the genetic information about known functional opioid receptor variants such as about the *OPRM1* rs1799971 SNP (118 A \> G; Chr6:154360797 in [Fig. 3](#f0015){ref-type="fig"}) as the so far scientifically most regarded variant possibly triggering reduced opioid efficacy or about the *OPRM1* rs563649 SNP (Chr6:154407967 in [Fig. 3](#f0015){ref-type="fig"}) coding for the μ-opioid receptor splice variant MOR-1K probably triggering opioid-induced hyperalgesia [@bb0215]. However, the full NGS information comprises a whole matrix composed of the single vectors and the evaluation and interpretation of this information requires bioinformatics approaches able to unleash the advances of NGS over single variant approaches as shown elsewhere [@bb0145].

4. Discussion {#s0045}
=============

A comprehensive NGS assay for the exons and regulatory parts of human opioid receptors was developed that produced valid nucleotide sequences corresponding to those obtained with the classical Sanger sequencing technique. The NGS assay is suitable for small to large-scale experimental setups aiming at accessing the information about any nucleotide in a study cohort, with a selection of those that differ from the reference nucleotide.

Single opioid receptor variants have been causally involved in reduced responses to analgesic treatment [@bb0220], hyperalgesic responses to opioid analgesics [@bb0225], protection against opioid induced side effects [@bb0230], [@bb0235], the individual sensitivity to painful stimuli [@bb0240], [@bb0245], the risk for drug addiction [@bb0250], [@bb0255], the individual response to stress [@bb0060], the success of naloxone treatment of alcoholism [@bb0260], or even the susceptibility to breast cancer [@bb0265] or the incidence of sudden infant death syndrome [@bb0270]. At the molecular level, in particular μ-opioid receptor variants have been shown to reduce opioid receptor expression [@bb0080], [@bb0085], receptor signaling [@bb0085], [@bb0090], [@bb0095] up to an almost complete functional loss [@bb0090], [@bb0100], and alternative splicing with the appearance of a six-transmembrane segment μ-opioid receptor [@bb0225] that triggers excitatory effects [@bb0215]. However, despite this apparently successful research on opioid receptor genetics, results have neither entered clinical practice nor have they been included in main treatment guidelines for pain or addiction [@bb0120], [@bb0275]. This may have several causes such as too small effect sizes counterbalanced by concomitantly other genetic variants [@bb0280]. However, an important perception of the discrepancy between the pathophysiological importance of opioid receptors including their role as main drug targets and the modest utility of their genotyping is, that the limited selection of published functional variants with accessibility by specific genetic assays [@bb0115] is probably insufficient. Indeed, we have recently shown that NGS of human opioid receptor genes outperforms single opioid receptor variants as a genetic biomarker of opioid-analgesia related phenotypes [@bb0145].

Research interest in the complete genomic information dates back to the seventies of the last century when the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication had been introduced [@bb0125], [@bb0130]. Techniques significantly improved during the last decades [@bb0285] with the development of contemporary machines in the late 1990s released to the market around the year 2005. The term "next generation" DNA sequencing refers to high-throughput technologies capable of parallel analyses of large numbers of different DNA sequences in a single reaction [@bb0290]. NGS has been attributed the potential to accelerate biomedical research [@bb0140], [@bb0295], [@bb0300]. Current leading manufacturers of commercial NGS platforms are Illumina (Genome Analyzer, HiSeq, MiSeq) and Life Technologies (SOLiD System, Ion Torrent, Proton). The systems combine conceptually similar workflows, starting with the creation of the genetic sample, which commences library preparation involving fragmentation of genomic DNA, purifying to uniform and desired fragment size and ligation to sequencing adapters specific to the platform. Differences apply to the reaction biochemistry and the way how the sequencing information is read [@bb0290]. In the present ion semiconductor sequencing method, libraries are immobilized to beads and amplified in microdroplets of aqueous solution and oil using emulsion PCR. Individual nucleotide bases are incorporated via DNA polymerase, which in the case of success triggers the release of a proton. The semiconductor chip that acts as a pH meter [@bb0305] providing the final readout. Alternative techniques use the detection of light instead, i.e., from optical fluorescence signals in the case of successful nucleotide incorporation the DNA nucleotide sequence is assembled. The different techniques differ with respect to the obtained throughput and accuracy [@bb0310], [@bb0315].

The high throughput and comprehensive information about DNA sequences are presently reflected in the assay costs. The sequencing of the opioid receptor genes of 79 patients required € 4500 for the AmpliSeq™ custom panel, € 5800 for library preparation, € 980 for template preparation and € 1200 for sequencing. In addition, approximately € 800 was spent for consumables and supplies. With twelve barcoded samples loaded on each chip, analysis costs for a single patient\'s opioid receptor gene sequence were approximately € 168. NGS costs are expected to quickly fall in near future [@bb0320]. However, despite this rapid technological progress, the analysis of the generated large data sets remains challenging [@bb0325]. As the sequencing process is only the beginning of the procedure, the analysis of the resulting "big data" requires substantial computational power, bioinformatics expertise and "up to date" databases of genomic variations. NGS technologies seem to shift the workload essentially away from the laboratory sample preparation toward various data analysis processes.

Research on the genetic variation of human opioid receptors as the main targets of endogenous and exogenous opioids is of immediate interest for assessing the clinical effects of opioid analgesics and for studying the epidemiology of substance addiction. The present NGS method is suitable for large-scale sequencing of an extended set of human genes belonging or related to opioid receptors. By covering almost the complete relevant coding and regulatory parts of the genes, the method includes all variants studied so far for functional associations and adds a large amount of genetic information as a basis for complete analysis of human opioid receptor genetics and its functional consequences.
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Supplementary tablesImage 1

Supplementary information includes (i) a list of PCR primer used for the NGS assay (Supplementary Table 1) and (ii) a list of missed parts from the opioid receptor gene panel (Supplementary Table 2). Supplementary data associated with this article can be found in the online version, at [doi:10.1016/j.cca.2016.10.009](http://dx.doi.org/10.1016/j.cca.2016.10.009){#ir0020}.

![Pseudo-color image of the Ion 316™ v2 Chip plate showing percent loading across the physical surface. This sequencing run had a 70% loading, which ensures a high ISP density. Every 316 chip contains more than 6 million wells and the color scale on the right side conduces as a loading indicator. Deep red coloration stays for a 100% loading which means that every well in this area contains an ISP (templated and non-templated) whereas deep blue coloration implies that the wells in this area are empty.](gr1){#f0005}

![The Figure shows the alignment of the ion torrent sequence of the κ-opioid receptor illustrated by Golden Helix Genome Browse® readout (A) versus the same sequence according to a Sanger electropherogram (B). The grey bars in panel A show the read depth of the single nucleotides (all nucleotide positions ≈ 300 reads). The green scale in panel A shows the amino acids from different transcripts in detail. The colored bars in Panel B indicate for a sequencing quality parameter, which means a high filled box means a trustworthy sequencing process.](gr2){#f0010}

![Example opioid receptors\' genetic pattern of 28 pain patients receiving standard opioid doses (extended from [@bb0145]). The plot shows the occurrence of variants (lines) per DNA sample (columns) as vectors of a length corresponding to the number of gene loci in which a non-reference nucleotide was found in any sample of the whole cohort. The vectors are composed of information about the number of non-reference alleles found at the respective locus in the respective sample, color codes as white, 0 non-reference alleles = wild type genotype, yellow, heterozygous, and red, 2 non-reference alleles. The opioid receptors are indicated by different color shading behind the vectors of individual genetic information.](gr3){#f0015}

###### 

AmpliSeq™ amplicons and coverage details of the human opioid receptor NGS assay.

Table 1

  Gene        Chr         Chr start   Chr end     Amplicons   Total bases   Covered bases   Coverage   Sum (total, covered, %)
  ----------- ----------- ----------- ----------- ----------- ------------- --------------- ---------- -------------------------
  *OPRD1*     Chr1        29138628    29139147    1           519           94              0.181      1924, 1336, 69.4%
  Chr1        29185440    29185840    2           400         292           0.730                      
  Chr1        29189228    29190233    6           1005        950           0.9453                     
  *OPRM1*     Chr6        154331605   154331719   1           114           114             1.000      23787, 21859, 91.8%
  Chr6        154331605   154332178   3           573         573           1.000                      
  Chr6        154360211   154360465   2           254         254           1.000                      
  Chr6        154360270   154360465   2           195         195           1.000                      
  Chr6        154360520   154360994   4           474         474           1.000                      
  Chr6        154360211   154360994   6           783         783           1.000                      
  Chr6        154407616   154408945   8           1329        1329          1.000                      
  Chr6        154407616   154408964   8           1348        1348          1.000                      
  Chr6        154410935   154411338   3           403         403           1.000                      
  Chr6        154410871   154411338   3           467         467           1.000                      
  Chr6        154412061   154412632   4           571         571           1.000                      
  Chr6        154412918   154413098   2           180         180           1.000                      
  Chr6        154414379   154414680   2           301         301           1.000                      
  Chr6        154428725   154428812   1           87          87            1.000                      
  Chr6        154428574   154428812   2           238         238           1.000                      
  Chr6        154429125   154430178   6           1053        865           0.8215                     
  Chr6        154428857   154430178   9           1321        1123          0.8501                     
  Chr6        154431464   154431613   1           149         149           1.000                      
  Chr6        154439792   154453514   72          13722       12180         0.88763                    
  Chr6        154567801   154568026   2           225         225           1.000                      
  *OPRK1*     Chr8        54138250    54142414    23          4164          3872            0.9299     5683, 5117, 90%
  Chr8        54147293    54147696    3           403         403           1.000                      
  Chr8        54155273    54155497    1           224         116           0.518                      
  Chr8        54163315    54163670    3           355         338           0.952                      
  Chr8        54163982    54164219    1           237         194           0.819                      
  Chr8        54163982    54164282    1           300         194           0.647                      
  *SIGMAR1*   Chr9        34634693    34635662    6           969           969             1.000      3520, 3427, 97.3%
  Chr9        34634693    34635880    8           1187        1187          1.000                      
  Chr9        34636968    34637111    1           143         143           1.000                      
  Chr9        34636968    34637134    1           166         166           1.000                      
  Chr9        34637238    34637442    2           204         204           1.000                      
  Chr9        34637191    34637442    2           251         251           1.000                      
  Chr9        34637578    34637848    2           270         251           0.930                      
  Chr9        34637518    34637848    2           330         256           0.776                      
  *OPRL1*     Chr20       62711445    62711730    2           285           230             0.807      3954, 3708, 93.7%
  Chr20       62716343    62716526    2           183         183           1.000                      
  Chr20       62717832    62717977    2           145         145           1.000                      
  Chr20       62723293    62723494    2           201         201           1.000                      
  Chr20       62724015    62724331    4           316         316           1.000                      
  Chr20       62729129    62729535    5           406         406           1.000                      
  Chr20       62729603    62732021    15          2418        2227          0.921                      

###### 

Ion Torrent PGM Run Characteristics (n = 7) of the NGS of human opioid receptor genes in n = 79 DNA samples obtained from pain patients.

Table 2

  Chip    Samples on chip   Loading density (%)   Total bases   Total Reads   Mean read length (bp)
  ------- ----------------- --------------------- ------------- ------------- -----------------------
  316_1   12                65                    502 M         2,949,673     170
  316_2   12                80                    220 M         1,755,623     125
  316_3   11                63                    339 M         2,060,050     165
  316_4   11                50                    406 M         2,374,049     171
  316_5   11                67                    540 M         3,186,425     169
  316_6   11                56                    477 M         2,813,274     170
  316_7   11                52                    495 M         2,645,442     174
